Category: Cardiology
-
ACC26: Amgen’s Repatha cuts first major CV event risk by 31%
New data show Repatha significantly reduces first heart attacks and strokes in high-risk patients without known significant plaque buildup.
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
2025 in Review: Global biotech and funding trends
Deepali Suri, President of ICON Biotech, discusses Asia’s clinical trial boom, funding shifts, and why neurology and cardiology are surpassing oncology.
-
Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation
The US FDA approves Stereotaxis’ robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.
-
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.
-
HeartBeam’s stock shows strong pulse after FDA clearance
A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.
-
Pharvaris stock rises following positive Phase III topline data
The company’s oral drug deucrictibant significantly sped up symptom relief in the Phase III trial, positioning it for 2026 regulatory filings.
-
Levron Medical emerges with new approach to treating heart failure
Following first-in-human results and new funding, the company prepares for a clinical study at Sheba Medical Center.
-
AHA 2025: Amgen’s Repatha cuts first heart event risk by 25%
Landmark trial shows Repatha significantly reduces major cardiovascular events in high-risk patients without prior heart attack or stroke.
-
CorVista’s test shows promise for early pulmonary hypertension diagnosis
The newly published case series highlights CorVista System’s ability to detect pulmonary hypertension earlier than traditional methods.
-
Stereotaxis boasts completion of first US robotic HD mapping procedure
Deborah Heart and Lung Center pioneers first US use of Stereotaxis’ MAGiC Sweep catheter for robotic arrhythmia mapping.
-
Merck’s oral PCSK9 inhibitor finds another Phase III success
The pivotal CORALreef Lipids trial assessing enlicitide in hypercholesterolemia patients met all primary and key secondary endpoints.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.